Determinants of health as predictors for differential antibody responses following SARS-CoV-2 primary and booster vaccination in an at-risk, longitudinal cohort
Echeverri Tribin, F.; Williams, E.; Testamarck, V.; Carreno, J. M.; Bielak, D.; Yellin, T.; Krammer, F.; Hoffer, M.; Pallikkuth, S.; Pahwa, S.
Show abstract
Post vaccine immunity following COVID-19 mRNA vaccination may be driven by extrinsic, or controllable and intrinsic, or inherent health factors. Thus, we investigated the effects of extrinsic and intrinsic on the peak antibody response following COVID-19 primary vaccination and on the trajectory of peak antibody magnitude and durability over time. Participants in a longitudinal cohort attended visits every 3 months for up to 2 years following enrollment. At baseline, participants provided information on their demographics, recreational behaviors, and comorbid health conditions which guided our model selection process. Blood samples were collected for serum processing and spike antibody testing at each visit. Cross-sectional and longitudinal models (linear-mixed effects models) were generated to assess the relationship between selected intrinsic and extrinsic health factors on peak antibody following vaccination and to determine the influence of these predictors on antibody over time. Following cross-sectional analysis, we observed higher peak antibody titers after primary vaccination in females, those who reported recreational drug use, younger age, and prior COVID-19 history. Following booster vaccination, females and Hispanics had higher peak titers after the 3rd and 4th doses, respectively. Longitudinal models demonstrated that Moderna mRNA-1273 recipients, females, and those previously vaccinated had increased peak titers over time. Moreover, drug users and half-dose Moderna mRNA-1273 recipients had higher peak antibody titers over time following the first booster, while no predictive factors significantly affected post-second booster antibody responses. Overall, both intrinsic and extrinsic health factors play a significant role in shaping humoral immunogenicity after initial vaccination and the first booster. The absence of predictive factors for second booster immunogenicity suggests a more robust and consistent immune response after the second booster vaccine administration.
Matching journals
The top 6 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Age and smoking predict antibody titres at 3 months after the second dose of the BNT162b2 COVID-19 vaccine 95%
- Attenuation of antibody titres during 3-6 months after the second dose of the BNT162b2 vaccine depends on sex, with age and smoking as risk factors for lower antibody titres at 6 months 95%
- Analysis of immunization, adverse events, and efficacy of a fourth dose of BNT162b2 vaccine 95%
Similar papers in this journal
- Determinants of the COVID-19 Vaccine Hesitancy Spectrum 95%
- COVID-19 vaccine access and attitudes among people experiencing homelessness from pilot mobile phone survey in Los Angeles, CA 94%
- COVID-19 vaccine hesitancy and refusal and associated factors in an adult population in Saskatchewan, Canada: Evidence from predictive modelling 94%
Similar papers in this journal
- COVID-19 vaccine hesitancy and conspiracy beliefs in Togo: Findings from two cross-sectional surveys 92%
- High confidence and demand for hepatitis E vaccine during an outbreak in Bentiu, South Sudan: A qualitative study 91%
- Predicting Mobile Health Clinic Utilization for COVID-19 Vaccination in South Carolina: A Statistical Framework for Strategic Resource Allocation 91%
Similar papers in this journal
- Factors associated with the decay of anti-SARS-CoV-2 neutralizing antibodies among recipients of an adenoviral vector-based AZD1222 and a whole-virion inactivated (BBV152) vaccine in Chennai, India: a prospective, longitudinal, cohort study 94%
- Poliovirus Vaccination Induces a Humoral Immune Response that Cross Reacts with SARS-CoV-2 92%
- Randomized, double blind, placebo controlled, clinical trial to study co-administration of Ashwagandha on safety, immunogenicity, and protection with COVID-19 vaccine – A Study Protocol 92%
Similar papers in this journal
- Immunogenicity and reactogenicity of mRNA COVID-19 vaccine booster administered by intradermal or intramuscular route in Thai Older adults 93%
- SARS-CoV-2 DNA Vaccine INO-4800 Induces Durable Immune Responses Capable of Being Boosted in a Phase 1 Open-Label Trial 92%
- Recombinant adjuvanted zoster vaccine and reduced risk of COVID-19 diagnosis and hospitalization in older adults 92%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.